AI-generated analysis. Always verify with the original filing.
Beam Therapeutics Inc. entered into a standby license agreement with Kobe University and Bio Palette Co., Ltd. on February 9, 2026, to ensure continued access to certain patents if the existing license between Kobe and Bio Palette terminates, with financial consideration payable directly to Kobe after such termination.
Event Type
Disclosure
Mandatory
Variant
8-K
Entry into a Material Definitive Agreement. As previously reported, Beam Therapeutics Inc. (the “Company”) and Bio Palette Co., Ltd. (“Bio Palette”) are parties
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 # Standby License Agreement between Beam Therapeutics Inc., Kobe University and Bio
Material Agreement